Glenmark to retain ISB 2001 rights in India, emerging markets;

IGI Therapeutics SA, a wholly-owned subsidiary of Ichnos Glenmark Innovation (IGI)—an alliance between Glenmark Pharma and Ichnos Sciences Inc.—has signed an exclusive licensing agreement with AbbVie for IGI’s lead investigational asset, ISB 2001, Glenmark Pharma said in an exchange filing on July 10. ISB 2001 has been developed using IGI’s proprietary BEAT protein platform for oncology and autoimmune diseases.

Source